Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01999985 · ClinicalTrials.gov registry record · Phase 1
Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)
A Phase 1 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT01999985 is a Phase 1 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 25 participants.
The verdict
NCT01999985, a Phase 1 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to: * Find out if the study drugs Afatinib and Dasatinib can be safely given together to patients with lung cancer * Learn how these two drugs work in cancer cells when they are combined * Learn more about the side effects of these two drugs when combined * Find the highest doses of the study drugs Afatinib and Dasatinib that can be given safely without causing serious side effects
Interventions
- DRUG Dasatinib - 1A
- DRUG Afatinib - 1A
- DRUG Dasatinib - 1B
- DRUG Afatinib - 1B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2013-12-31 |
| Est. Completion | 2019-05-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01999985
The ClinicalTrials.gov registry entry for NCT01999985 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Dasatinib - 1A is the first listed.
NCT01999985 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01999985 about?
NCT01999985 is a clinical study titled "Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)". The purpose of this study is to: * Find out if the study drugs Afatinib and Dasatinib can be safely given together to patients with lung cancer * Learn how these two drugs work in cancer cells when they are combined * Learn more about the side effects of these two drugs when combined * Find the hig...
What is the current status of trial NCT01999985?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2013-12-31. Estimated completion is 2019-05-30.
What interventions are being tested in trial NCT01999985?
The interventions under investigation include: Dasatinib - 1A (DRUG), Afatinib - 1A (DRUG), Dasatinib - 1B (DRUG), Afatinib - 1B (DRUG).
Who is sponsoring clinical trial NCT01999985?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.